AAV patients on BDB-001 achieve remission, cut corticosteroid use
Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while reducing the need for standard glucocorticoids. That’s according to new data from a Phase 1/2 clinical trial conducted in China. Glucocorticoids, also commonly called corticosteroids, are a standard AAV…